Baxdrostat Cuts BP Significantly in Hard-to-Control Hypertension

The BaxHTN phase III trial's full results were positive; patients with hard-to-control (uncontrolled and resistant) hypertension who received baxdrostat or placebo in addition to standard of care showed a statistically significant and clinically meaningful reduction in mean seated systolic blood pressure (SBP) at 12 weeks when compared with placebo.

These findings were concurrently published in the New England Journal of Medicine and presented during a Hot Line session at the 2025 European Society of Cardiology (ESC) Congress.

Baxdrostat met the primary and all secondary endpoints in the BaxHTN Phase III trial, delivering meaningful and sustained blood pressure reductions in patients with hard-to-control hypertension.

At week 12, the absolute reduction from baseline in mean seated SBP was 15.7 mmHg (95% confidence interval [CI], -17.6 to -13.7) and placebo-adjusted reduction was 9.8 mmHg (95% CI, -12.6 to -7.0; p<0.001) for the 2mg dose.

The absolute and placebo-adjusted reductions for the 1 mg dose were 14.5 mmHg (95% CI, -16.5 to -12.5) and 8.7 mmHg (95% CI, -11.5 to -5.8; p<0.001) from baseline, respectively. When using a placebo, the mean sitting SBP decreased by 5.8 mmHg (95% CI: -7.9 to -3.8). Both the uncontrolled and treatment-resistant populations showed consistent results.

Also Read: Zilebesiran to Be Tested in High-Risk Hypertension Trial

In comparison to placebo (0.0%), baxdrostat was generally well accepted, showed no unexpected safety concerns, and had modest rates of confirmed hyperkalaemia (>6 mmol/L in both dosing groups [1.1% each]). The majority of side effects were minor, and baxdrostat's safety profile aligned with its mode of action.